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Overview  
 
The context surrounding prostate cancer has changed drastically in the last three decades. This is largely 
due to discoveries allowing identification of patients earlier in the disease course and newer, novel 
therapies to treat patients at different stages in the disease. However prostate cancer management, and 
in particular screening, is not without controversy. Owing to a supposed indolent nature of a large 
percentage of diagnosed tumours the need for a screening program and early identification of patients 
has been questioned. To this end a selective screening program has been suggested to target sub 
population groups at increased risk for aggressive disease (of note is that Black African individuals are 
considered an at-risk group for aggressive prostate cancer).  How and if this should be affected has still 
not been established. The South African based Prostate Cancer Foundation recommends general 
population PSA based screening after the age of forty-five years (with screening after the age of forty 
years in males deemed at increased risk), however there are no guidelines on screening from the National 
Department of Health. To date most studies undertaken locally have included a cohort that does not 
accurately reflect the population of South Africa (these studies were based in the Western Cape and had 
a selection bias towards White males). Of the two studies undertaken in KwaZulu-Natal, one was 
undertaken in a general hospital with a 'satellite' Urology department. The other study assessed prostate 
biopsy waiting times as its primary outcome. In this descriptive study, a review of the outcome of prostate 
biopsies at a regional hospital for a two-year period was undertaken to establish if there is evidence either 
for a general or sub population specific serum PSA based prostate cancer screening program and what 
guidelines should govern such a program. This was accomplished by comparing the incidence of prostate 
cancer amongst the different racial groups of patients undergoing a prostate biopsy at St. Aidan’s Mission 
Regional Hospital and specifically looking at the number of patients with advanced disease as well as the 
initial serum PSA readings the patients presented with. Patients referred to St. Aidan’s Mission Regional 
Hospital for a prostate biopsy represent a cohort of patients who largely were referred after an 
opportunistic serum PSA test was performed at the referring healthcare facility. It was found that nearly 
two thirds of patients had a positive cancerous histology after the first biopsy with more than 90% of 
patients diagnosed with prostate cancer being risk stratified to a category requiring some form of either 
curative or palliative treatment. 
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Chapter 1: Introduction 
 
Introduction 
The face of prostate cancer has changed in the last 30 years. Initially a disease where late presentation 
and high mortality was the norm, the paradigm has shifted due to numerous discoveries in the preceding 
years. At one end of the spectrum the discovery of PSA and its approval for the use in prostate cancer 
treatment and screening in the late 1980s and early 1990s enabled clinicians to identify ‘early’, in some 
cases pre-symptomatic disease. The resultant effect was the reduction in prostate cancer mortality (with 
an increase in diagnosis and treatment) (1, 2).  
Literature review 
However, with the increase in histologically confirmed, organ confined disease, it also became readily 
apparent that the burden of new prostate cancer cases was skewed towards low grade, seemingly 
indolent disease with possibly little aggressive potential within a patient’s lifetime (1-3). This trend in 
“over diagnosis” of prostate cancer lead to suggestions that screening of prostate cancer with serum PSA 
readings should be abandoned (3, 4). Studies done to establish consensus initially further confounded the 
issue by offering seemingly juxtaposed results and therefore conclusions. The European Randomised 
Study of Screening for Prostate Cancer (ERSPC)(5) revealed an 8.2% incidence of prostate cancer in the 
routine PSA screening group (versus 4.8% prostate cancer incidence in the control group). PSA based 
screening reduced prostate cancer mortality by 20%. To effect this however the estimation from this study 
was that 1410 men would need to have PSA screening for prostate cancer with 48 additional cases of 
Prostate cancer diagnosed to prevent one death from prostate cancer(1). These are the quoted figures 
from the nine year follow up of the ERSPC study. The figures from the 16 year follow up are that 570 men 
need to be screened with 18 additional cases of prostate cancer diagnosed to prevent one death from 
prostate cancer(6).  
 
The 2010 Göteborg Prostate Cancer Screening Trial(7) findings were in congruence with the ERSPC, with 
293 men needing to be screened and twelve new cases of prostate cancer diagnosed to prevent one death 
from prostate cancer. In comparison the figures quoted for breast cancer screening is that one additional 
death from breast cancer will be prevented with every 400 patients screened (between the ages of 50-70 
years)(8). The data and initial conclusions from the Prostate, Lung, Colorectal and Ovarian (PLCO) trial 
however, did not demonstrate any significant reduction in prostate cancer related mortality(1). A review 
of the data in the ERSPC and PLCO trials by Tsodikov et al however using mean lead time estimations, and 
accounting for differences in implementation and setting, revealed that both studies provided compatible 
evidence that screening reduces prostate cancer mortality(9). 
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The results of these findings should be considered with the conclusions gained from other prostate cancer 
studies. Prostate cancer screening and indeed PSA based prostate cancer screening may still not be 
indicated for the general male population despite the findings of the ERSPC, Göteborg or PLCO. “The risk 
of a fifty year old man with a 25 year life expectancy of having microscopic cancer is 42%, of having 
clinically evident cancer 9,5% and of dying of prostate cancer 2,9%.” (4). However a man in his forties with 
three close relatives diagnosed with prostate cancer (e.g. father, uncle and brother) has a 30-40% lifetime 
risk of developing clinically significant disease (4). It would therefore appear that prostate cancer 
screening should be directed to subsets of the population that are deemed at risk. The need for criteria in 
terms of which sub population groups qualify for a biopsy is important as a prostate biopsy is not an 
innocuous procedure (4, 10). Sepsis and heamaturia are two common complications with sepsis rates on 
average of 1-7% reported and heamaturia rates of between 2-34%. 
Use of the Serum PSA level to decide on the need for a biopsy is in itself fraught with difficulties (11). 
Factors often cited against a PSA screening program are the poor specificity of PSA as a bio-marker of 
prostate cancer, the likelihood that a biopsy proven cancer may not be clinically significant and actually 
indolent in nature and that a prostate biopsy by its nature is a very invasive procedure fraught with many 
potential complications (12, 13).PSA can be considered prostate disease specific and not necessarily 
prostate cancer specific. Various factors can cause a raised PSA, among them infection of the prostate, 
urinary tract instrumentation and prostate malignancy. To further cloud the use of PSA a poorly 
differentiated prostate cancer may actually not secrete any PSA or may even secrete a reduced amount 
in comparison to a normal prostate cell. A PSA value between 0-4ng/ml is commonly accepted as a 
“normal PSA”. Further to this there has also been suggestions that higher PSA cut offs should be deemed 
age appropriate (14). However in a study of 332 men who were fifty years or older with serum PSA value 
between 2.6-4ng/ml, prostate biopsies revealed cancer in 22% of them (4). A study by Oesterling 
suggested that PSA range of 0-4.5 should be appropriate for men 60-69 years of age while a PSA of 0-6.5 
should also be normal for men 70-79 years of age. It therefore should be considered “safe” to omit 
biopsies in these men with these PSA readings (assuming the digital rectal examination is normal). 
However a retrospective review of prostate biopsies (14) contradicted this, revealing that if this protocol 
had been followed 60% of aggressive cancers would be missed.  
Despite the controversies of whether general prostate cancer screening should be instituted or indeed 
how prostate cancer screening should be carried out, certain sub population groups are at greater risk for 
the development of the disease either purely by a predisposing genetic risk factor, lack of awareness of 
the disease or both of these factors. To this extent people of Black African ancestry represents one such 
sub group.  
In the USA the lifetime risk of the general male population for prostate cancer is 15,9% and the risk of 
death is 2,8% (15). The incidence in African American men is almost 60% higher however then the general 
American population with the mortality being 2-3 times greater. Even in the pre PSA screening era the 
mortality rate amongst African American men was 55 per 100000 while in White American men it was 29 
per 100000 (1) indicating that African American men have a more aggressive disease type independent of 
early detection. African American men have a strong West African ancestry. There is evidence to suggest 
that there is a disproportionate larger burden of disease in West African men (15). In men of African 
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ancestry prostate cancer may in fact transform into aggressive disease earlier than White men. Even 
studies such as the PCLO and ERSPC trial which initially revealed no or marginal benefit of screening for 
prostate cancer were underpowered for Black African population.  There was an estimated 28006 deaths 
from prostate cancer in Africa in 2010 and this number is calculated to rise to 57048 deaths in 2030, an 
increase of 104% (16).  
However based purely on figures from the World Health Organisation worldwide cancer data, West 
African men have a lower prostate cancer incidence and mortality compared to African American men 
(17). The quagmire is rendered further murkier by a reported higher prostate cancer mortality rate in the 
Afro-Caribbean population – a population sharing a genetic ancestry to West African men. Is this increase 
in West African descendants due purely to environmental and dietary factors or could it be still be due to 
a genetic link? Men with African ancestry who reside in the Americas and the Caribbean nations by and 
large can trace their ancestry to the Transatlantic Slave Trade. The present-day countries from which 
individuals were captured for slavery are Benin, Nigeria, Ghana, Gambia, Senegal, Mozambique and 
Angola. Therefore, it is likely that the population of the Americas and the Caribbean nations that claim 
Black African ancestry likely have a genetic mixture from the above African countries and are not just 
purely West African. The last two mentioned African countries are geographically neighboring countries 
to South Africa. Furthermore, Odedina et al(17) found that the World Health Organization cancer data for 
African countries (and indeed developing countries in general) may be under reported and not accurate. 
The true prevalence and incidence therefore may be higher, and the role of environmental factors limited 
(17, 18).  
The PROCESS study (18), carried out at selective sites in and around London in the United Kingdom, 
compared the incidence and prevalence of prostate cancer in the different ethnic groups inhabiting the 
United Kingdom. In addition to merely comparing the Black race to the White race in terms of incidence 
and prevalence it went further by actually comparing Black males of Caribbean origin to Black males 
originating from the African continent. Census data indicated that Black UK males are largely first-
generation migrants from either the Caribbean or Africa (by and large West Africa) therefore allowing a 
head to head analysis of these groups. The findings of the PROCESS study were congruent with other 
studies by revealing that Black men in general had a higher relative risk of developing prostate cancer 
than their White counterparts (this risk was more marked for younger men). The risk was still less than 
that seen for Black men in the United States. There was no statistically difference in prostate cancer 
incidence in Black Caribbean and Black African men.  
Owing to British/European colonialism of the Caribbean and South Africa, the ethnic make-up of the 
populations of both these regions are similar with Black males of African origin and Asian males with roots 
from the Indian subcontinent(12). A study done in Tobago (17) revealed that the Black population (of 
West African descent) had a significantly higher prevalence when compared to the Asian-Indian group. 
The age group looked at was between 50-64 year age group. A study conducted in the UK including the 
Indian-Asian population as well as the Black and White population (17, 18) revealed similar data with the 
Indian-Asian population having the lowest incidence of Prostate Cancer, the White population a similarly 
low incidence of prostate cancer and the Black population a significantly higher incidence and risk.  
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Previous studies on PSA based general population screening for Prostate Cancer were underpowered to 
reflect a Black population of African origin. Given the increased incidence, younger age at presentation 
and more aggressive disease pattern a PSA screening program for the Black African population or a general 
population PSA screening program in a country with a majority Black African population may actually 
prove worthwhile and cost effective (12). Even a targeted screening program of these at-risk men with 
PSA and then further bio, gene or radiological markers to direct which patients would then qualify for a 
biopsy appears to be the next logical step (13). The other confounding factor with PSA that should be 
considered is race specific PSA with the purported higher baseline PSA levels in Black African men 
regardless of age and Prostate Cancer status. Despite this it has been cited by Jyoti et al. that the use of 
traditional PSA cutoff threshold values would result in 40% of cancers being missed (12) (This article cites 
an article by Morgan et al however the footnote in the reference section corresponds to an article by 
Speights et al). 
An additional compounding factor adding to the aggressive disease seen in Black men is the lack of 
knowledge of prostate cancer or PSA screening. In a study done by Nathaniel Mofolo et al. (19) only 39,5% 
of Black African patients in that study had indicated that they had heard of prostate cancer. A study by 
Elizabeth A. Tindall et al. (20) revealed that patients in Limpopo presented later and with more aggressive 
prostate cancer due to lack of PSA awareness and testing. This can have the knock-on effect of Black 
patients not seeking PSA screening when latent disease may be at a curative stage or of even not going 
on to have a prostate biopsy, even when counselled that a biopsy is indicated. In a study by Heyns et al. 
(3) only 19% of Black patients requiring a biopsy underwent the procedure versus 47% of Coloured (mixed 
ethnicity) patients. The study by Le Roux et al. (21) in a peri-urban setting in KwaZulu-Natal 66% of Black 
African men had incurable disease in stark contrast to a study in California USA where 6% of African 
American patients had metastatic disease. This drastic increased incidence of metastatic prostate cancer 
in the KwaZulu-Natal study population may in part be due to the late presentation of patients (the mean 
age of patients in the study by Le Roux et al. was seventy-one years, in the American SEER data base mean 
age of presentation is sixty-four years). The other conclusion of Le Roux et al. made was that prostate 
cancer was under diagnosed in this region (there were only 81 diagnosed cases of prostate cancer over 
the 24-month period, out of an estimated 150000 men over forty years of age in the region). This again in 
part can be attributed to the lack of awareness of prostate cancer and PSA screening. The reliance on 
traditional medicine before allopathic remedies are sought, could be another contributory factor.  
The impact of genetic predisposition to prostate cancer in general and aggressive forms of the disease is 
just beginning to be investigated. Vanessa Hayes in conjunction with other authors has published three 
papers (22-24) looking at the role unique genes present in the South African Black male may play in 
causing a phenotype of early and or aggressive prostate cancer. Early work on a small sample of patients 
has demonstrated the association between high risk prostate cancer (defined by the authors as gleason 
>=8 prostate cancer or Serum PSA >=20) and a subset of genes believed to code for this aggressive disease. 
 
The economic effect of treating metastatic prostate cancer is another factor that should be considered. 
The modern treatment of metastatic prostate cancer has rendered it almost akin to a chronic disease 
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rather than a rapidly progressing fatal malignancy. However even the most basic first line treatment for 
metastatic prostate cancer - Androgen Deprivation Therapy - has a cost on average of R6000 per 
treatment (with the patient required to take the treatment every three months, lifelong thereafter). 
Patients are on this treatment until their death and during the course of treatment may require the 
addition of other medications as the cancer progresses. A national prostate cancer screening program, 
that utilises serum PSA, may likely allow the detection of prostate cancer at an earlier stage in the course 
of the disease. This would result in more patients being offered curative treatment and the knock-on 
effect of this would likely be a cost saving to both Government and private sector health care funders 
alike.  
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Research Question 
What is the incidence of prostate cancer in the patient population presenting to St. Aidan’s Hospital 
(general and by individual race)? What is the incidence of intermediate, high risk and metastatic prostate 
cancer (general patient population and by race)? What is the relationship between serum PSA and the 
diagnosis of prostate cancer? 
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Chapter 2:  RETROSPECTIVE REVIEW OF PROSTATE BIOPSIES AT A REGIONAL 
LEVEL HOSPITAL  
 
Abstract 
Background 
Prostate cancer is a leading cause of male mortality worldwide and its incidence is on the increase. 
Evidence currently points to there being an increased risk of developing the disease amongst Black African 
males. Prostate cancer studies done in South Africa to date have not however included cohorts that 
accurately reflect the demographics of South Africa i.e. a majority Black African population. 
Objectives 
To gauge if there is an increased risk in incidence of clinically significant prostate cancer amongst Black 
African males and if this does exist whether this supports the use of a Serum PSA based population 
screening program in South Africa.  
Methods 
A retrospective review was carried out of the outpatient charts of patients who underwent a prostate 
biopsy at St. Aidan’s Mission Regional Hospital between the period 01 January 2016 to 31 December 2017. 
Pertinent data was recorded and analysed with SPSS. 
Results 
Of the 205 outpatient files analysed (mean age 68,6 years), 61% of these belonging to Black African 
patients, 136 patients (66,34%) were found to have prostate cancer – 133 patients were diagnosed with 
cancer after the first biopsy and the other 3 patients on subsequent biopsies. Almost 40% of the patients 
diagnosed with prostate cancer had evidence of metastases with 25% of the cancer patients not having 
their metastatic status confirmed (often due to them defaulting follow up). Patients referred to St. Aidan’s 
Mission Regional hospital for prostate biopsy represent patients who underwent opportunistic PSA 
screening at their base healthcare facility. 
Conclusion 
The significantly higher incidence of prostate cancer (and intermediate to high risk and metastatic 
prostatic cancer) seen in our study consisting of a cohort with a majority of Black African patients (61,95%) 
compared to similar South African studies with cohorts more representative of a European country (i.e. a 
small percentage of Black African patients) infers that the Black African male is at increased risk of Prostate 
Cancer and that there would likely be a benefit from a Serum PSA based Prostate Cancer screening 
program.  Further studies are recommended to provide definitive evidence to support this hypothesis. 
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INTRODUCTION 
 
Prostate cancer is one of leading causes of mortality in males worldwide. The estimated global burden of 
disease will see almost two million new cases by the year 2030 with almost 500000 deaths(1-3). In 
addition, the economic burden of treating prostate cancer is likely to be immense as newer novel 
therapies allow even metastatic disease to be managed as a chronic condition. With this in mind emphasis 
should be placed on a screening program in at-risk populations to improve the diagnosis and treatment 
of disease in the early stages(4). Multiple observational studies have concluded that men with Black 
African ancestry represent an at-risk population for the onset of prostate cancer at an earlier age and with 
a more aggressive subtype(3, 5-7). Very few studies have been carried out in Africa that have looked at 
the incidence and prevalence of prostate cancer in either the general population or specific ethnic 
population groups(8). Some of the population-based studies carried out in South Africa examining the 
incidence and prevalence of prostate cancer consisted of cohorts underpowered for the Black African 
ethnic population group(9, 10).  As the majority population group in South Africa the true extent of 
prostate cancer and its impact will not be known until more studies with a more accurate South African 
demographic are undertaken.  
The chronicity of metastatic prostate cancer, gifted by advances in treatment, have seen healthcare costs 
escalate. This life extending treatment itself is not without significant side effects and adverse events. As 
a developing economy, South Africa needs to rationalize the use of its health care budget. Screening 
programs to pick up and treat premalignant precursor conditions or even to allow the diagnose and 
treatment of cancer at early curative stage may be the way in which this is accomplished.  Previous studies 
that have examined the possibility of general population screening studies for prostate cancer have shown 
a benefit, albeit with a large number of patients having to be screened just to prevent one death(1, 11). 
These studies however also consisted of cohorts underpowered with patients of Black African ancestry.  
It is likely that a general population-based screening program in a society with a large Black African 
population may require a smaller number of patients to be screened to reduce the death rate from 
prostate cancer. In order to assess the viability of such an intervention a study to first gauge the incidence 
of prostate cancer and advanced Prostate cancer should be undertaken.  The aim of this study is to report 
the incidence of prostate cancer and advanced prostate cancer over a two-year period in the cohort of 
patients referred to St. Aidan’s Mission hospital for prostate biopsies. The catchment area of St. Aidan’s 
Mission Hospital Urology department is wide and far reaching and encompassing most of the province of 
KwaZulu-Natal  (only the catchment areas of Pietermaritzburg, Ngwelezane, Newcastle and Ladysmith do 
not refer to St. Aidan’s hospital but instead to the tertiary hospitals located in those towns. 
 
METHODS: 
This study was designed to be a quantitative, observational, descriptive study. As such a retrospective 
review of outpatient records was undertaken to obtain the data. All patients undergoing a prostate biopsy 
at the St. Aidan’s Urology clinic had their details (name, out-patient folder number) recorded in a 
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procedure book kept by the clinic nursing staff. This book was perused, and a list was compiled of patients 
eligible for the study i.e. those who underwent a biopsy from the period 01 January 2016 to 31 December 
2017. Thereafter the relevant patients’ files were requested from the hospital registry department. A total 
of 215 patients were identified as eligible for accrual into the study, however only 206 of these patients’ 
files could be located. The normal protocol for a prostate biopsy at St. Aidan’s Hospital is for each patient 
to have a 12 core (6 cores per lobe) biopsy of the prostate on an outpatient basis under a peri-prostatic 
block, via a transrectal ultrasound to visualize the prostate. Once a patient was accrued into the study the 
outpatient chart for that patient was analysed and the data surrounding the index biopsy (i.e. the biopsy 
performed in 2016-2017), all preceding biopsies and/or all subsequent biopsies were recorded.  
The primary aim of the study was to determine the racial profile of prostate cancer amongst the patients 
referred for prostate biopsy and to support or refute the hypothesis that the Black African male is at 
increased risk both in terms of incidence of prostate cancer and aggressive forms of the disease. To this 
end the race of the patients in the study was determined by the main investigator and the nursing sister 
assisting him with data collection by analysing both the patients name and a copy of his ID document. 
Patients have never being asked to self-assign their race at the hospital (as stated in a previous study 
performed at the same institution(12)). The study was also geared towards risk stratifying patients 
diagnosed with prostate cancer between Low, Intermediate and High-risk groups in order to assess the 
proportion of patients diagnosed with so called clinically significant prostate cancer. 
Permission to conduct the study was obtained from the hospital management and National Health 
Research Department. Ethical approval to conduct the study was obtained from the Biomedical Ethics 
Committee of University of KwaZulu-Natal(BREC REF NO: BE464/18). 
Measurements 
The patients demographics (date of birth, race), the date the patient was first seen, initial PSA, digital 
rectal examination findings, date of prostate biopsy and results of the biopsy (benign hypertrophy versus 
prostate cancer versus Infection and Gleason score of tumour if malignancy present), any documented 
post biopsy complications (e.g. Sepsis, Heamaturia, Acute Urinary Retention) the patient may have 
experienced, bone scan results (if done) and the chosen treatment option were recorded. Patients with a 
clinically abnormal feeling prostate on rectal examination had a T stage assigned according to the AJCC 
TNM staging system for prostate cancer by the doctor who had seen them (13). Using a combination of 
the patients T stage, Gleason score and initial serum PSA value at diagnosis patients were risk stratified 
according to the D’Amico classification system (14). Race was determined based on a combination of 
patients’ appearance in their ID photo together with their name/surname and the opinion of the lead 
investigator and his data collection assistant. The waiting period from first consultation to the first 
prostate biopsy was calculated based on the dates of the two events. 
Data Collection and Statistical Analysis 
Data was obtained by reviewing urology outpatient department charts of patients who underwent a 
prostate biopsy during the period under consideration. Data initially was recorded onto a “data sheet” 
(See Appendices) and thereafter was entered from the data sheet onto an Excel spreadsheet to allow for 
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easier analysis of the data. The Excel spread-sheet had been stored on a password-protected computer 
that only the primary investigator had access to. Once obtained the data was analysed with the aid of 
SPSS with the assistance of one of the co-supervisors.  
RESULTS:  
A total of 205 patients were accrued into the study of which 127 were Black African men (40 were Indian, 
23 were White and nine were Coloured). The race of 6 patients could not be determined. The ages of the 
patients varied from 40 years to over 80 years old with the majority of the patients (93) lying in the 60-
69-year age group.   The mean PSA at presentation was 460,2 ng/ml (the median PSA was 32,2). The 
majority of the patients were clinically staged to having T1 prostate on digital rectal examination (Table 
1). 
Table 1: Clinical T-Stage of Patients 
 Number Percent 
 T1c 62 30.1 
T2a 33 16.0 
T2b 12 5.8 
T2c 12 5.8 
T3a 19 9.2 
T3b 3 1.5 
T4 43 20.9 
T Stage 
Unknown 
21 10.7 
 TOTAL 205 100 
 
The outcomes from the first biopsy are indicated in Table 2. Prostate cancer was found in 64,9 % of 
patients.  
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Table 2: Outcomes of First Biopsy 
 Frequency Percent 
 Cancer 133 64.9 
BPH 15 7.3 
Chronic prostatitis 50 24.4 
ASAP 3 1.5 
No prostate tissue 4 2.0 
Total 205 100.0 
 
A second biopsy was indicated in 15 patients for reasons of a persistent elevated PSA (n=9), suspicious 
DRE with a negative biopsy (n=2), no prostate tissue in the first biopsy (n=3) and due to inability to locate 
the results from the first biopsy (n=1). However only 14 patients underwent the repeat biopsy (one patient 
defaulted). Of these 14 patients 3 were diagnosed with cancer (5 patients had BPH, 5 patients had chronic 
prostatitis and 1 patient had ASAP). Only 2 patients underwent a third biopsy with one patient having 
prostate cancer on his histology results and the other patient ‘s histology revealing BPH. Therefore, after 
considering all the biopsy findings out of 205 patients 66,3% (n=136) had prostate cancer with 33,7% 
(n=69) having a non-cancerous histological diagnosis. 
Of the 136 patients diagnosed with prostate cancer 39,7% had radiologically or bone scan confirmed 
metastases, 35,3% of the prostate cancer patients had no metastases with 25% of the patients not having 
their metastatic status determined for a variety of reasons (often because the patients defaulted follow-
up). After risk stratification using the D’Amico classification 35,3% of prostate cancer patients fell into the 
Organ Confined High Risk grouping and 39,7% of prostate cancer patients had metastatic disease (Figure 
1). 
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Figure 1: D'Amico Risk Stratification 
 
A crosstabulation of D’Amico risk stratification versus chosen treatment options revealed the following: 
Table 3: Crosstabulation between D'Amico and Chosen Treatment 
MANAGEMENT CODED * D'AMICO Crosstabulation 
 
D'AMICO 
Total 
OC-Low 
risk 
OC-
Intermediate 
risk 
OC-High 
risk 
Locally 
Advanced Metastatic 
MANAGEMENT 
CODED 
WW Count 0 1 0 0 0 1 
% of Total 0.0% 0.7% 0.0% 0.0% 0.0% 0.7% 
RP Count 1 0 0 0 0 1 
% of Total 0.7% 0.0% 0.0% 0.0% 0.0% 0.7% 
BT Count 0 2 1 0 0 3 
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% of Total 0.0% 1.5% 0.7% 0.0% 0.0% 2.2% 
EBRT Count 2 7 14 0 0 23 
% of Total 1.5% 5.1% 10.3% 0.0% 0.0% 16.9% 
ADT Count 1 3 22 13 52 91 
% of Total 0.7% 2.2% 16.2% 9.6% 38.2% 66.9% 
BSO Count 0 0 1 0 1 2 
% of Total 0.0% 0.0% 0.7% 0.0% 0.7% 1.5% 
CHEMO Count 0 0 0 0 1 1 
% of Total 0.0% 0.0% 0.0% 0.0% 0.7% 0.7% 
UNKNOWN Count 0 1 10 3 0 14 
% of Total 0.0% 0.7% 7.4% 2.2% 0.0% 10.3% 
 
Sixty-two patients underwent a biopsy purely for a raised PSA (i.e. the DRE findings of the patients 
revealed benign feeling glands). Of this result twenty-two patients had positive biopsies for prostate 
cancer (32,25%). In patients with an abnormal DRE finding (One hundred and forty-three patients in total), 
positive biopsies for prostate cancer were found in one hundred and fourteen patients (79,7% of 
abnormal DRE patients).  This revealed a significant association between abnormal DRE and positive 
biopsy result - P < 0.001 (chi squared). 
The use of PSA to detect metastatic disease revealed that PSA is a good test for detecting metastatic 
disease (P<0.001) -see receiver operator curve below. The optimum PSA cut off point for metastatic 
disease was 100.4ng/ml (Youden Index). 
- 14 - 
 
 
Area under curve:    0.81 
Figure 2: Receiver Operator Curve For Performance of PSA to Detect Metastatic Disease 
 
Table 4: Association between PSA >= 100ng/ml and Metastatic Disease  
METASTASES * PSA 100 CODED Crosstabulation 
 
PSA 100 CODED 
Total No Yes 
METASTASES No Count 46 5 51 
% within METASTASES 90.2% 9.8% 100.0% 
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% within PSA 100 CODED 71.9% 11.4% 47.2% 
% of Total 42.6% 4.6% 47.2% 
Yes Count 18 39 57 
% within METASTASES 31.6% 68.4% 100.0% 
% within PSA 100 CODED 28.1% 88.6% 52.8% 
% of Total 16.7% 36.1% 52.8% 
Total Count 64 44 108 
% within METASTASES 59.3% 40.7% 100.0% 
% within PSA 100 CODED 100.0% 100.0% 100.0% 
% of Total 59.3% 40.7% 100.0% 
 
Table 5: Predictive Value of PSA >= 100ng/ml and Metastatic Disease 
 P < 0.001 
Sensitivity 68.4% 
Specificity 90.2% 
PPV 88.6% 
NPV 71.9% 
 
It was found that there was no significance in the age of presentation of the Black African patients 
compared to the Non-Black patients (Black 68.4 years vs Non-black 68.7 years). There was however a 
significant difference in the mean PSA that Black African patients presented with compared to their non-
Black counterparts (Black 491ng/ml vs. Non-Black 210.4 ng/ml). Furthermore, there was no association 
between the Black African race group and any specific Gleason grade groupings (3+3,3+4,4+3,4+4,9-10), 
neither was it found that the Black African race group was an independent risk factor that increased the 
risk of metastatic disease in prostate cancer.  
DISCUSSION: 
The St. Aidan’s Mission Regional Hospital Urology department (located in Durban) is the referral center 
for Urological patients for most of the province of KwaZulu-Natal (seven out of eleven health districts in 
the province refer Urology patients to St. Aidan’s hospital urology department). Based on population data 
obtained from the KZN Health Website(15) this equates to 5 875 683 people residing in these districts 
serviced by St. Aidan’s hospital. Male patients referred to St. Aidan’s Hospital Urology for any illness 
related to their prostate gland fall into three groups that are not mutually exclusive. These individuals 
either have a raised PSA that is normally performed by way of opportunistic screening (i.e. the patient will 
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present to their base hospital with some other complaint and not specifically seeking a medical opinion 
for prostate cancer and will then have a serum PSA level test performed), they may be referred specifically 
for lower urinary tract symptoms refractory to medical therapy (including them being catheter 
dependent) or lastly them may be referred with heamaturia for further assessment. Opponents to PSA 
screening often quote literature that a PSA based screening program will result in unnecessary prostate 
biopsies revealing either no cancer or low risk cancer that would not be clinically significant within a 
patient’s lifetime (1, 2, 4, 10).  
All patients (bar six) referred to St. Aidan’s Hospital Urology and who eventually underwent a biopsy had 
an opportunistic PSA screening performed at their base health care facility and were therefore referred 
due to a raised serum PSA level as at least one of the reasons for referral. From the 6 patients who were 
referred to St. Aidan’s Hospital Urology department for other reasons only 1 of these patients had a 
prostate biopsy revealing prostate cancer.  Data adjusted for this excluding the above patients reveals 
positive prostate cancer biopsies in 135 patients out of 199 patients biopsied (increasing the percentage 
of patients with cancer to 67,83%).   Of the 136 patients with histological proven prostate cancer 97,1% 
of patients were risk stratified according to the D’ Amico classification into a risk grouping that required 
some form of intervention for their cancer either in the form of curative therapy or palliative hormonal 
manipulation (age of the patient not considered), i.e. these patients did not have so called indolent low 
risk cancers (16, 17). Of note is that four patients had the T stage recorded as T4 clinically which would 
have indicated an advanced cancer, but their biopsies did not reveal any cancer. All four patients 
underwent only one biopsy that was not repeated after their initial histology was reviewed. Three of the 
patients were Black African and of these three, one patient did not have any prostate tissue represented 
in his biopsy (the other two had histology results revealing BPH and BPH chronic prostatitis respectively). 
One possible explanation for this is the hypothesis that Black African men have a higher concentration of 
prostate cancer in the anterior part of the prostate (18)– a region that may not be sampled conventionally 
on trans rectal ultrasound guided prostate biopsy. This has however not been proved conclusively. The 
other patient, an Indian male, had a histological diagnosis of BPH/Chronic Prostatitis. Furthermore, it has 
been found that in patients with an initial negative prostate biopsy for cancer, a repeat biopsy may reveal 
cancer in up to 23% of cases(9). 
A PSA screening study done by Heyns et al (9) were by patients were invited specifically to have PSA 
screening performed and thereby undergo a biopsy if indicated (either due to raised PSA, abnormal DRE 
or both) revealed prostate cancer in 32% (37 patients) out of 114 patients biopsied. The patient 
demographics in that study did not reflect those of the South African population at large i.e. 69% Black 
African, 18% White, 11% coloured/mixed race and 4% Indian)(19). This was acknowledged by the paper’s 
authors. The demographics of patient seen in our cohort are more reflective of the national population.  
The study by Heyns et al also found that 41,3% of patients who underwent prostate biopsy for a raised 
PSA only had prostate cancer (compared to our figure of 32,25%). In comparison in the ERSPC study 30,2% 
of men biopsied purely for a raised PSA had prostate cancer. However, of 2365 patients, in the ERSPC 
study, who underwent biopsy for a either a raised PSA or abnormal DRE finding only 21,4% of patients 
were diagnosed with prostate cancer compared to the 64,9% seen in our study after the first biopsy (and 
66,3% when considering the repeat biopsies). The prostate cancer percentage in the Heyns study after 
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the first biopsy was 32,5%. This may be partly explained by the use of a sextant prostate biopsy template 
(20) that was employed in that study (three cores taken from each lobe of the prostate), compared to the 
six cores taken in each lobe of the prostate in our study. The other explanation is the racial disparities 
seen in the Heyns study and our study in terms of patients biopsied (with our study having a majority 
Black African population that underwent prostate biopsy).  
The management options by percentage chosen for patients with potentially curative (localized) disease 
in the Heyns screening study (9) were Watchful Waiting in 62,5% of patients, Radiotherapy in 20,8% of 
patients and Radical Prostatectomy in the remaining 16,7% of patients i.e. curative treatment was chosen 
by only 37,5% of patients. This differs greatly for the ERSPC study in which 89% of patients with organ 
confined/localized disease chose a curative modality of treatment (radiotherapy 51%, radical 
prostatectomy 38%) and is also in stark contrast to our study were only 19,8% of patients with organ 
confined disease chose a curative treatment modality. It should be noted that this percentage is made up 
of three patients that underwent Prostate Brachytherapy a treatment modality that does not form part 
of the standard treatment options on offer at St. Aidan’s Hospital. These patients benefitted from a 
teaching workshop hosted by a private company BARD that also donated the brachytherapy seeds. 
Another study by Heyns et al looked at PSA as a surrogate for a prostate biopsy in the diagnosis of cancer 
(21). The study concluded that a PSA of >=60ng/ml had a positive predictive value of 98%, specificity 98% 
and a sensitivity of 65% for the presence of Prostate Cancer. A PSA of 100ng/ml had a positive predictive 
value of 99%, specificity of 99% and a sensitivity of 53%. The association between PSA values and positive 
metastases was not investigated however. Taking into account the findings from our current study this 
would suggest that a PSA of 100ng/ml can be taken as surrogate of both prostate cancer diagnosis and of 
diagnosing metastatic disease. The mean waiting period for a biopsy in our cohort was 102 days. The study 
done by Singh et al (12) looking at a cohort in the same institution during 2013 revealed a prostate biopsy 
waiting time of 55 days. This would indicate that the biopsy waiting time has almost doubled and therefore 
would negatively affect patients by delaying their time to diagnosis. However, our biopsy time does 
include one outlier who waited 2605 days for his biopsy (the reason for this waiting time is unknown). 
With this outlier removed the waiting period for a prostate biopsy decreases to 89 days. Furthermore our 
study was conducted over a two year period while the study by Singh et al (12) was conducted over a six 
month period. Our longer period of review probably indicates a more accurate reflection of the actual 
waiting time for a prostate biopsy at this facility rather than indicating a worsening of the quality of the 
prostate biopsy service at St. Aidan’s Hospital.   
Our findings of Black African patients presenting with a significantly higher PSA than other races is 
congruent with other studies done in KZN (12), elsewhere in South Africa (9, 10, 22) and the world (3, 5-
7, 20). However despite this the reason (or reasons) for this correlation has still not been conclusively 
proven; whether the reason is that Black African men present with larger prostate volumes compared to 
other race groups or if there a defect in the prostate acinar cell basement membrane of  Black African 
men that causes these higher serum PSA levels is still unknown. 
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CONCLUSION: 
Although the data accrued by us did not initially seem to suggest that the Black African race group was 
more at risk for Prostate Cancer in general or even at an increased risk for metastatic prostate cancer the 
higher incidence of histologically diagnosed prostate cancer and high grade cancer diagnosed in our 
cohort (that was made up of 61,95% of patients from the Black African race group) compared to other 
similar studies infers that the Black African male is likely at an increased risk for prostate cancer both in 
terms of incidence of prostate cancer and higher grade of cancer seen. The study by Heyns et al (9) while 
based in South Africa (the Western Cape province) demonstrated a cohort more akin to the population of 
a European/Western country. Similarly, the findings of that study were more reproducible of the findings 
of other European/Western based PSA screening studies. 
A study done by Cooner et al. (23) revealed a prostate cancer detection rate of 14,6% in a clinic population 
of symptomatic urological patients i.e. patients referred for a urological opinion and treatment – our 
finding of cancer detection rate of 66,3% is more than triple of that rate. The study of Cooner et al. (23) 
collated data from private urologists serving the general American population and was therefore likely 
made up of a population of majority White males. Therefore, even if the argument that our study 
population represents a symptomatic population of urology patients rather than a population of patients 
referred specifically for a prostate biopsy after an opportunistic PSA screening was done, is considered, 
our incidence is still substantially higher.   Globally there is enough evidence to suggest that there should 
be some type of PSA based prostate screening program in a population made up of individuals whose 
ethnicity contains that of the Black African race group.  
Of note is that almost 40% of the 136 patients diagnosed with Prostate cancer had confirmed metastases 
at diagnosis (25% of the prostate cancer patients did not have their metastatic status confirmed therefore 
the actual number could be much higher than 40%). It is unlikely that these patients developed de novo 
metastatic disease and with 58% of the patients biopsied being below 70 years of age an active effort 
should be made to diagnose patients with prostate cancer before the development of metastases. By and 
large the patients who underwent biopsy in this study did so due to a raised PSA being found as a result 
of opportunistic PSA testing. A formal PSA screening program should be developed given that PSA has a 
higher specificity than mammography does for breast cancer detection(20), there is enough data to 
support that the Black African male is at increased risk for prostate cancer in general and aggressive forms 
of prostate cancer in particular, and that the Black African race group is the predominate race in South 
Africa. The Göteborg Trial(24), consisting of two cohorts of patients made up almost exclusively from the 
White ethnic group, estimated that 293 men would have to be screened with 12 newly diagnosed cases 
of prostate cancer to prevent one death from it (reported in that trial as been comparable in numbers to 
breast and colon cancer screening data). This is from cumulative prostate cancer incidence rates of 12,7% 
in the screening group and 8,2% in the control (non-screened) group. With our prostate cancer incidence 
of 66,3% the number needed to be screened and the number of patients diagnosed to prevent death in 
our context would likely be significantly lower thus making a Serum PSA based screening program more 
cost effective. 
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This study is constrained however as the biopsy data we have presented is only a reflection of the 
population seeking public healthcare as a source of diagnosis and treatment. We do not have the biopsy 
data of patients in our referral areas who would have underwent a prostate biopsy by a private urologist 
(with the tissue being processed by a private laboratory). Furthermore, even though 215 patients 
underwent a prostate biopsy over the period in question this does not mean that only 215 patients 
required a prostate biopsy during that period. The limiting factor to the number of patients that undergo 
a prostate biopsy is the staff complement and the availability of equipment. Over the period in question 
prostate biopsies were performed once a week with generally only up to 10 patients being biopsied every 
week. Therefore, we suggest that further comprehensive studies be undertaken to examine the above 
hypothesis that a serum PSA screening study will be of benefit in a population were the majority 
population group is Black African. Amongst these studies we suggest: 
- Collating the prostate biopsy data from the other Urology referral centers, draining the rest of the 
province of KwaZulu-Natal, to demonstrate or refute the findings in our study.  
- Reviewing the prostate biopsy data from the private laboratories in KwaZulu-Natal over a defined period 
and correlating it with the PSA readings for the patients that underwent a prostate biopsy. 
-A PSA screening study with patients invited to screen and undergo a biopsy if indicated. 
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EXECUTIVE SUMMARY 
 
 
Statement of purpose 
 
The context surrounding Prostate Cancer has changed drastically in the last three decades. This 
is largely due to discoveries allowing identification of patients earlier in the disease course and 
newer, novel therapies to treat patients at different stages in the disease. However prostate 
cancer management, and in particular screening, is not without controversy.  Owing to a 
supposed indolent nature of a large percentage of diagnosed tumours the need for a screening 
program and early identification of patients has been questioned. To this end a selective 
screening program has been suggested to target sub population groups at increased risk for 
aggressive disease (of note is that Black African individuals are considered an at-risk group for 
aggressive prostate cancer).  How and if this should be affected has still not been established. 
The South African based Prostate Cancer Foundation recommends general population PSA based 
screening after the age of forty-five years (with screening after the age of forty years in males 
deemed at increased risk), however there are no guidelines on screening from the National 
Department of Health. The purpose of this descriptive study is to review the outcome of prostate 
biopsies at a regional hospital for a two-year period to establish if there is evidence either for a 
general or sub population specific PSA based prostate cancer screening program and what 
guidelines should govern such a program. To date most studies undertaken locally have included 
a cohort that does not accurately reflect the population of South Africa (these studies were based 
in the Western Cape and had a selection bias towards White males). Of the two studies 
undertaken in KwaZulu-Natal, one was undertaken in a general hospital with a 'satellite' Urology 
department. The other study assessed prostate biopsy waiting times as its primary outcome.  
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1. BACKGROUND AND LITERATURE REVIEW 
1.1 Defining the Clinical Problem 
Prostate cancer is one of leading causes of mortality in males worldwide. The estimated global 
burden of disease will see almost two million new cases by the year 2030 with almost 500000 
deaths. In addition, the economic burden of treating prostate cancer is likely to be immense as 
newer novel therapies allow even metastatic disease to be managed as a chronic condition. With 
this in mind emphasis should be placed on a screening program in at risk populations to improve 
the diagnosis and treatment of disease in the early stages.  
 
1.2 The literature review  
 
The face of prostate cancer has changed in the last 30 years. Initially a disease were late 
presentation and high mortality was the norm, the paradigm has shifted due to numerous 
discoveries in the preceding years. At one end of the spectrum the discovery of PSA and its 
approval for the use in prostate cancer treatment and screening in the late 1980s and early 1990s 
gifted clinicians with the means to identify ‘early’, in some cases pre symptomatic disease. The 
resultant effect was the reduction in prostate cancer mortality (with an increase in diagnosis and 
treatment) [1, 2].  
 
However, with the increase in histologically confirmed, organ confined disease, it also became 
readily apparent that the burden of new prostate cancer cases was skewed towards low grade, 
seemingly indolent disease with possibly little aggressive potential within a patient’s lifetime [1-
3]. This trend in “over diagnosis” of prostate cancer lead to suggestions that screening of prostate 
cancer with serum PSA readings should be abandoned [3, 4]. Studies done to establish consensus 
initially further confounded the issue by offering seemingly juxtaposed results and therefore 
conclusions. The European Randomised Study of Screening for Prostate Cancer (ERSPC) revealed 
an 8.2% incidence of prostate cancer in the routine PSA screening group (versus 4.8% prostate 
cancer incidence in the control group). PSA based screening reduced prostate cancer mortality 
by 20%. To affect this however the estimation from this study was that 1410 men would need to 
have PSA screening for prostate cancer with 48 additional cases of Prostate cancer diagnosed to 
prevent 1 death from prostate cancer [1]. 
 
The 2010 Göteborg Prostate Cancer Screening Trial findings were in congruence with the ERSPC, 
with 293 men needing to be screened and 12 new cases of prostate cancer diagnosed to prevent 
one death from prostate cancer. In comparison the figures quoted for breast cancer screening is 
that one additional death from breast cancer will be prevented with every 400 patients screened 
(between the ages of 50-70 years) [5]. The data and initial conclusions from the Prostate, Lung, 
Colorectal and Ovarian (PLCO) trial however, did not demonstrate any significant reduction in 
prostate cancer related mortality [1]. A review of the data in the ERSPC and PLCO trials by 
Tsodikov et al however using mean lead time estimations, and accounting for differences in 
implementation and setting, revealed that both studies provided compatible evidence that 
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screening reduces prostate cancer mortality [6]. 
 
The results of these findings should be considered with the conclusions gained from other 
prostate cancer studies. Prostate cancer screening and indeed PSA based prostate cancer 
screening may still not be indicated for the general male population despite the findings of the 
ERSPC, Göteborg or PLCO. “The risk of a fifty-year-old man with a 25-year life expectancy of 
having microscopic cancer is 42%, of having clinically evident cancer 9,5% and of dying of prostate 
cancer 2,9%.” [4]. However, a man in his forties with three close relatives diagnosed with prostate 
cancer (e.g. father, uncle and brother) has a 30-40% lifetime risk of developing clinically 
significant disease [4]. It would therefore appear that prostate cancer screening should be 
directed to subsets of the population that are deemed at risk. The need for criteria in terms of 
which sub population groups qualify for a biopsy is important as a prostate biopsy is not an 
innoxious procedure [4, 7]. Sepsis and heamaturia are two common complications with sepsis 
rates on average of 1-7% reported and heamaturia rates of between 2-34%. 
 
Use of the Serum PSA level to decide on the need for a biopsy is in itself fraught with difficulties. 
PSA can be considered prostate disease specific and not necessarily prostate cancer specific. 
Various factors can cause a raised PSA among them infection of the prostate, urinary tract 
instrumentation and prostate malignancy. To further cloud the use of PSA a poorly differentiated 
prostate cancer may actually not secrete any PSA or may even secrete a reduced amount in 
comparison to a normal prostate cell. A PSA value between 0-4ng/ml is commonly accepted as a 
“normal PSA”. Further to this there has also been suggestions that higher PSA cut offs should be 
deemed age appropriate [8]. However, in a study of 332 men who were fifty years or older with 
serum PSA value between 2.6-4ng/ml, prostate biopsies revealed cancer in 22% of them [4]. A 
study by Oesterling suggested that PSA range of 0-4.5 should be appropriate for men 60-69 years 
of age while a PSA of 0-6.5 should also be normal for men 70-79 years of age. It therefore should 
be considered “safe” to omit biopsies in these men (assuming the digital rectal examination is 
normal). However, a retrospective review of prostate biopsies [8] contradicted this revealing that 
if this protocol had been followed 60% of aggressive cancers would be missed.  
 
Despite the controversies of whether general prostate cancer screening should be instituted or 
indeed or how prostate cancer screening should be carried out, certain sub population groups 
are at greater risk for the development of the disease either purely by a predisposing genetic risk 
factor, lack of awareness of the disease or both of these factors. To this extent people of Black 
African ancestry represents one such sub group.  
 
In the USA the lifetime risk of the general male population for prostate cancer is 15,9% and the 
risk of death is 2,8% [9]. The incidence in African American men is almost 60% higher however 
then the general American population with the mortality being 2-3 times greater. Even in the 
pre-PSA screening era the mortality rate amongst African American men was 55 per 100000 while 
in White American men it was 29 per 100000 [1]. African American men have a strong West 
African ancestry. There is evidence to suggest that there is a disproportionate larger burden of 
disease in West African men [9]. In men of African ancestry prostate cancer may in fact transform 
into aggressive disease earlier than White men. Even studies such as the PCLO and ERSPC trial 
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which initially revealed no or marginal benefit of screening for prostate cancer were 
underpowered for Black African population.  There was an estimated 28006 deaths from prostate 
cancer in Africa in 2010 and this number is calculated to rise to 57048 deaths in 2030, an increase 
of 104% [10]. 
 
The other compounding factor adding to the aggressive disease seen in Black men is the lack of 
knowledge of Prostate Cancer or PSA screening. A study done by Nathaniel Mofolo et al. [11] only 
39,5% of Black African patients in that study had indicated that they had heard of prostate cancer. 
A study by Elizabeth A. Tindall et al. [12] revealed that patients in Limpopo presented later and 
with more aggressive prostate cancer due to lack of PSA awareness and testing. This can have 
the knock-on effect of Black patients not seeking PSA screening when latent disease may be at a 
curative stage or even of not going on to have a prostate biopsy even when counselled that a 
biopsy is indicated. In study by Heyns et al. [3] only 19% of Black patients requiring a biopsy 
underwent the procedure versus 47% of coloured (mixed ethnicity) patients. The study by Hugo 
Le Roux et al. [13] in a peri-urban setting in KwaZulu-Natal 66% of Black African men had incurable 
disease in stark contrast to a study in California USA where 6% of African American patients had 
metastatic disease. This drastic increased incidence of metastatic prostate cancer in the KwaZulu-
Natal study population may in part be due to the late presentation of patients (the mean age of 
patients in the study by Le Roux et al. was seventy-one years, in the American SEER data base 
mean age of presentation is sixty four years). The other conclusion of Le Roux et al. was that 
prostate cancer was been under diagnosed in this region (there were only 81 diagnosed cases of 
prostate cancer over the 24-month period, out of a estimated 150000 men over forty years of 
age in the region). This again in part can be attributed to the lack of awareness of prostate cancer 
and PSA screening. The reliance on traditional medicine before allopathic remedies are sort, 
could be another contributory factor.  
 
The economic effect of treating metastatic prostate cancer is another factor that should be 
considered. The modern treatment of metastatic prostate cancer has rendered it almost akin to 
a chronic disease rather than a rapidly progressing fatal malignancy. However even the most 
basic first line treatment for metastatic prostate cancer - Androgen Deprivation Therapy - has a 
cost on average of R6000 per treatment. Patients are on this treatment until their death and 
during the course of treatment may require the addition of other medications as the cancer 
progresses. A national screening program with the emphasis been on early stage pick up and 
curative treatment may in the long-term result on health expenditure saving to both Government 
and the private sector funders.  
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2. AIMS AND OBJECTIVES 
Aim: To describe the burden of disease of prostate cancer and establish the outcomes of prostate 
biopsies at St. Aidan’s Hospital Urology department during the period of 01 January 2016 to 31 
December 2017. 
 
Objectives: 
1. To determine the demographics of patients undergoing prostate biopsy at St. Aidan’s Mission 
Hospital. 
2. To determine the patient characteristics and cancer parameters of patients diagnosed with 
prostate cancer. 
3. To assess the sensitivity and specificity of a PSA >4ng/mL for detecting prostate cancer in the 
patient groups having prostate cancer. 
4. To determine the relationship between PSA level and the likelihood of detecting prostate 
cancer in the patient groups presenting to St. Aidan’s hospital. 
5. To calculate the total cost of Androgen Deprivation Therapy, for two years, for all prostate 
cancer patients initiated onto it from the study group.  
 
 
3. METHODS 
3.1. Study Design 
 
The study will be a designed to be a quantitative, observational, descriptive study using a 
retrospective review of records. 
      
3.2. Setting 
 
The study will be conducted using the files of patients’ attending the St. Aidan’s Mission Regional 
Hospital Urology out patients department.  Permission has been obtained from hospital 
management.  
3.3. Participant Selection and Sampling Strategy 
All patients who underwent a prostate biopsy in the period 2016-2017 will be accrued as a 
participant for the study irrespective if the biopsy was an initial or repeat biopsy. Once a patient 
is accrued into the study the patients outpatient chart will be analysed and the data surrounding 
the index biopsy (i.e. the biopsy performed in 2016-2017),  all preceding biopsies and/or all 
subsequent biopsies will be recorded. 
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3.4. Measurements 
Data recorded will be of the patients demographics (date of birth, race), the date the patient was 
first seen, initial PSA, digital rectal examination findings, prostate biopsy results (benign 
hypertrophy versus prostate cancer versus Infection and Gleason score of tumour if malignancy 
present), any documented post biopsy complications (e.g. Sepsis, Heamaturia, Acute Urinary 
Retention) the patient may have experienced, bone scan results (if done) and the chosen 
treatment option. Race will be determined based on a combination of patients’ appearance in 
their ID photo together with their name/surname and the opinion of the lead investigator and 
the nursing sister assisting him with data collection.  
 
 
3.5. Data Collection and Statistical Analysis 
Data will be obtained from review of urology outpatient department charts of patients who 
underwent a prostate biopsy during the period under consideration. Data will initially be 
recorded onto a “data sheet” (See Appendices) and will be entered from the data sheet onto an 
Excel spreadsheet at a later date to allow for easier analysis of the data. The Excel spreadsheet 
will be stored on a password-protected computer that only the primary investigator has access 
to. Once the data is obtained the assistance of a statistician will be sort to further interpret the 
data with the use of descriptive statistics and graphs. 
 
 
 
 4. ETHICAL CONSIDERATIONS 
Patient Confidentiality and Protection: 
All patient data is to be obtained retrospectively from outpatient charts with no direct patient 
interaction. Data obtained from the charts will not direct further management of patients. No 
further testing will be performed on patients. Patient’s data will be kept confidential and 
recorded on a password-protected computer.  
 
Patient Benefits: 
The findings of this study may help to shape future prostate cancer screening guidelines thereby 
assisting the population at large by allowing the disease to be diagnosed and treated earlier, 
resulting in an improved life expectancy and quality of life. The patients, however, from whose 
charts data will be obtained, will unlikely benefit further from the findings of this study.  
 
Conflict of interest: 
No funding has been obtained from any private organisations (drug company or otherwise) with 
a vested interest in any potential outcomes. This study will be used to complete the research 
obligations of an MMED degree but there is no bias to any particular findings. 
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5. METHODOLOGICAL CHALLENGES AND STUDY LIMITATIONS 
- Outpatient charts for patients shown in records to be biopsied may not be able to be found. 
- Not all information needed for study may have been recorded. 
-The race of all patients may not be determined therefore impacting on the findings of the 
study.  
 
6. FEASIBILITY 
There is no foreseeable monetary cost to the study. Files will be analyzed and the required data 
recorded by a nursing sister from St. Aidan’s Hospital (Sister K. Chetty) and myself. Statistical 
assistance will be sort from the biomedical research department of UKZN. 
 
7. STUDY SIGNIFICANCE 
It is hoped that the findings of this study will add weight to the increasing evidence that there 
should be a nationally sanctioned prostate screening program in South Africa due to a large sub 
population group of Black African males. Furthermore, as a result of the high cost of treatment 
for metastatic prostate cancer, addressing it at an earlier, curable stage may reduce both the 
direct and indirect economic burden of the disease. 
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Appendix 2: Data Collection Sheet 
Prostate Biopsy Details 
Name: __________________                DOB: __________            Race: ________ 
Hospital Number: _____________ 
Reason Referred:  ______________  Date 1st Presentation: _________ 
TUC Dependent: ___ Date of Biopsy: _________ Initial PSA: ________ 
T Stage:  _______  Initial Urea: _____     Initial Creatinine: ______ 
Diabetic: _____  Hypertensive: ___  Biopsy Sepsis: ______ 
Biopsy Left: _________    
Biopsy Right: _________  
Repeat Biopsy: _____ 
Reason for Repeat Biopsy: _____________  Date repeat Biopsy: ______ 
Biopsy Left: _______ Biopsy Right: _______ Biopsy Sepsis: _______ 
Bone Scan: _______________________________________________________ 
Initial Management: ____________________________________________ 
Date of Progression: ________  Castrate Resistant: _____  
Testosterone Level: ____ Antiandrogen: _____  
Date of Progression on AA: ________  Date Oncology Referral: ________ 
Reason Referred: ________ Date Surgery: _______  
Surgery Gleason Score: _________ LAST PSA: ___________ 
Last Date Patient seen: _______ Last Urea:  _____ Last Creatinine: ____ 
Catheter Dependent Last Visit: ____  Post Prostatectomy Incontinence: ____ 
Known Demised: _____  Likely Demised From Prostate Cancer: ______ 
